小児用医薬品の世界市場：洞察、競合情勢、市場予測：2030年

世界の小児用医薬品の市場規模は、2024年～2030年の予測期間中に4.79％のCAGRで拡大すると予測されています。小児用医薬品市場は、小児における急性および慢性疾患の有病率の上昇、小児人口の増加に伴う小児用医薬品の臨床試験数の増加、小児用医薬品の安全性と使いやすさの向上への注目の高まりなどの要因により、予測期間（2024年～2030年）中に小児用医薬品市場の顕著な収益成長をもたらすと予想されます。

小児の間でHIV、結核、マラリアなどの感染症が増加していることは、小児用医薬品の成長を促進する主な要因の1つです。ユニセフが2022年に提供したデータによると、2022年に世界で推定3,840万人のHIV感染者のうち、273万人が0～19歳の子どもです。同資料によると、2022年には世界中で毎日約850人の子どもがHIVに感染しています。

世界保健機関（WHO）の2022年の発表によると、世界中で毎年約40万人の0歳から19歳の子供や青年ががんに罹患しており、すべてのがんの中で白血病、脳腫瘍、リンパ腫、神経芽細胞腫やウィルムス腫瘍などの固形腫瘍が小児がんの最も一般的なタイプです。

当レポートでは、世界の小児用医薬品市場について調査し、市場の概要とともに、適応症別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 小児用医薬品市場レポートのイントロダクション

第2章 小児用医薬品市場のエグゼクティブサマリー

第3章 規制分析

第4章 小児用医薬品市場の主な要因分析

• 小児用医薬品市場の促進要因
• 小児用医薬品市場の抑制要因と課題
• 小児用医薬品市場の機会

第5章 小児用医薬品市場におけるポーターのファイブフォース分析

第6章 小児用医薬品市場に対するCOVID-19の影響分析

第7章 小児用医薬品市場の概要

• 適応症別
• 投与経路別
• 流通チャネル別
• 地域別

第8章 小児用医薬品市場の企業と製品プロファイル

• Viatris Inc.
• Sanofi
• GSK plc.
• Novartis AG
• AstraZeneca
• Johnson & Johnson Services
• Bayer AG
• Bristol-Myers Squibb Company
• Cipla Inc.
• BioMarin Pharmaceutical Inc.
• Sumitomo Pharma Co., Ltd
• Gilead Sciences, Inc.
• Takeda Pharmaceutical Company Limited
• ORPHELIA Pharma
• Pfizer Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Mestra Pharma
• F. Hoffmann-La Roche Ltd
• UCB S.A.
• Supernus Pharmaceuticals, Inc.

第9章 KOL の見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Pediatric Drugs Market
• Table 3: Pediatric Drugs Market in Global (2021-2030)
• Table 4: Pediatric Drugs Market in Global by Indication (2021-2030)
• Table 5: Pediatric Drugs Market in Global by Route of Administration (2021-2030)
• Table 6: Pediatric Drugs Market in Global by Distribution Channels (2021-2030)
• Table 7: Pediatric Drugs Market in Global by Geography (2021-2030)
• Table 8: Pediatric Drugs Market in North America (2021-2030)
• Table 9: Pediatric Drugs Market in North America by Country (2021-2030)
• Table 10: Pediatric Drugs Market in the US (2021-2030)
• Table 11: Pediatric Drugs Market in Canada (2021-2030)
• Table 12: Pediatric Drugs Market in Mexico (2021-2030)
• Table 13: Pediatric Drugs Market in Europe (2021-2030)
• Table 14: Pediatric Drugs Market in Europe by Country (2021-2030)
• Table 15: Pediatric Drugs Market in France (2021-2030)
• Table 16: Pediatric Drugs Market in Germany (2021-2030)
• Table 17: Pediatric Drugs Market in the United Kingdom (2021-2030)
• Table 18: Pediatric Drugs Market in Italy (2021-2030)
• Table 19: Pediatric Drugs Market in Spain (2021-2030)
• Table 20: Pediatric Drugs Market in the Rest of Europe (2021-2030)
• Table 21: Pediatric Drugs Market in APAC (2021-2030)
• Table 22: Pediatric Drugs Market in APAC by Country (2021-2030)
• Table 23: Pediatric Drugs Market in China (2021-2030)
• Table 24: Pediatric Drugs Market in Japan (2021-2030)
• Table 25: Pediatric Drugs Market in India (2021-2030)
• Table 26: Pediatric Drugs Market in Australia (2021-2030)
• Table 27: Pediatric Drugs Market in South Korea (2021-2030)
• Table 28: Pediatric Drugs Market in Rest of APAC (2021-2030)
• Table 29: Pediatric Drugs Market in the Rest of the World (2021-2030)
• Table 30: Pediatric Drugs Market in RoW by Region (2021-2030)
• Table 31: Pediatric Drugs Market in the Middle East (2021-2030)
• Table 32: Pediatric Drugs Market in Africa (2021-2030)
• Table 33: Pediatric Drugs Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Pediatric Drugs Market
• Figure 3: Pediatric Drugs Market in Global (2021-2030)
• Figure 4: Pediatric Drugs Market in Global by Indication (2021-2030)
• Figure 5: Pediatric Drugs Market in Global by Route of Administration (2021-2030)
• Figure 6: Pediatric Drugs Market in Global by Distribution Channels (2021-2030)
• Figure 7: Pediatric Drugs Market in Global by Geography (2021-2030)
• Figure 8: Pediatric Drugs Market in North America (2021-2030)
• Figure 9: Pediatric Drugs Market in North America by Country (2021-2030)
• Figure 10: Pediatric Drugs Market in the US (2021-2030)
• Figure 11: Pediatric Drugs Market in Canada (2021-2030)
• Figure 12: Pediatric Drugs Market in Mexico (2021-2030)
• Figure 13: Pediatric Drugs Market in Europe (2021-2030)
• Figure 14: Pediatric Drugs Market in Europe by Country (2021-2030)
• Figure 15: Pediatric Drugs Market in France (2021-2030)
• Figure 16: Pediatric Drugs Market in Germany (2021-2030)
• Figure 17: Pediatric Drugs Market in the United Kingdom (2021-2030)
• Figure 18: Pediatric Drugs Market in Italy (2021-2030)
• Figure 19: Pediatric Drugs Market in Spain (2021-2030)
• Figure 20: Pediatric Drugs Market in the Rest of Europe (2021-2030)
• Figure 21: Pediatric Drugs Market in APAC (2021-2030)
• Figure 22: Pediatric Drugs Market in APAC by Country (2021-2030)
• Figure 23: Pediatric Drugs Market in China (2021-2030)
• Figure 24: Pediatric Drugs Market in Japan (2021-2030)
• Figure 25: Pediatric Drugs Market in India (2021-2030)
• Figure 26: Pediatric Drugs Market in Australia (2021-2030)
• Figure 27: Pediatric Drugs Market in South Korea (2021-2030)
• Figure 28: Pediatric Drugs Market in Rest of APAC (2021-2030)
• Figure 29: Pediatric Drugs Market in the Rest of the World (2021-2030)
• Figure 30: Pediatric Drugs Market in RoW by Region (2021-2030)
• Figure 31: Pediatric Drugs Market in the Middle East (2021-2030)
• Figure 32: Pediatric Drugs Market in Africa (2021-2030)
• Figure 33: Pediatric Drugs Market in South America (2021-2030)
• Figure 34: Market Drivers
• Figure 35: Market Barriers
• Figure 36: Marker Opportunities
• Figure 37: PORTER'S Five Force Analysis

Pediatric Drugs Market By Indication (Respiratory Diseases, Cancer, Neurological Diseases, Genetic Diseases, And Others), By Route Of Administration (Oral, And Parenteral), By Distribution Channels (Hospital And Retail Pharmacy, E-Commerce, And Others), by geography is estimated to growth at a remarkable CAGR during the forecast period from 2024-2030 owing to rising number of pediatric patients suffering from multiple diseases and increasing research and development activities

The global pediatric drugs market is estimated to grow at a CAGR of 4.79% during the forecast period from 2024 to 2030. The pediatric drugs market is slated to witness prosperity owing to factors such as the rising prevalence of acute and chronic diseases among children, the increasing number of clinical trials for pediatric drugs coupled with the increasing child population, and the growing focus on improving the safety and usability of pediatric drugs are further expected to result in the appreciable revenue growth in the pediatric drugs market during the forecast period (2024-2030).

Pediatric Drugs Market Dynamics:

The rising prevalence of infectious diseases such as HIV, tuberculosis, malaria, and others among children is one of the major factors driving the growth of pediatric drugs. As per the data provided by UNICEF 2022, worldwide, out of an estimated 38.4 million cases of HIV in 2022, 2.73 million cases were of children aged between 0-19. As per the same source, every day nearly around 850 children became infected with HIV in 2022 across the globe.

As per World Health Organization 2022, worldwide around 400,000 children and adolescents aged between 0 and 19 years develop cancer each year and out of all cancers leukemias, brain cancers, lymphomas, and solid tumors, such as neuroblastoma and Wilms tumors are the most common types of childhood cancers.

The number of pharmaceutical trials going on for pediatric drugs is likely to assist the growth of the pediatric drug market. For example, Evrysdi (risdiplam, RG7916) is an investigational oral SMN2 splicing modifier being studied in the treatment of spinal muscular atrophy in pediatric patients by F. Hoffmann-La Roche Ltd. in partnership with PTC Therapeutics and SMA Foundation.

However, side effects associated with pediatric drugs and stringent regulatory policies may act as a restraint in the growth of the pediatric drugs market.

The pediatric drugs market reported a short period of a setback in the market growth owing to the implementation of the lockdown as a necessary step to stop the spread of COVID-19 infection. This led to a decline in the development and manufacturing of pediatric drugs owing to a shortage of raw materials. However, with the resumption of activities across industries including the healthcare and pharmaceutical sector, there has been a rising demand for pediatric drugs owing to the resumption of activities. The post-COVID scenario is going to be healthy for pediatric drugs and is expected to grow during the forecast period from 2024-2030.

Pediatric Drugs Market Segment Analysis:

Pediatric Drugs Market by Indication (Respiratory Diseases, Cancer, Diabetes, Genetic Diseases, and Others), Route of Administration (Oral and Parenteral), Distribution Channels (Hospital and Retail Pharmacy, E-Commerce, and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the route of administration segment of the pediatric drugs market, the oral category is projected to register a significant growth in revenue in the pediatric drugs market during the forecast period (2024-2030).

This can be ascribed to the advantages associated with the oral route of administration of drugs in pediatric patients. Oral administration of drugs in children is non-invasive and non-painful as compared to the parenteral route of administration and hence more acceptable by both parents and their children.

It is the simplest and safest method of administering drugs to children and does not cause severe reactions. It does not require training and is less objectionable than the parenteral method in the case of pediatric patients.

Also, the increasing research and development activities w.r.t. oral pediatric drugs are going to provide a conducive environment for the growth of the pediatric drugs market.

For instance, In March 2022, Pfizer Inc. announced that it has started Phase II/III Study of Novel COVID-19 Oral Treatment in Pediatric Participants. The study aims to evaluate the safety, pharmacokinetics, and efficacy of Pfizer's PAXLOVID(TM) in non-hospitalized, symptomatic, pediatric participants with a confirmed diagnosis of COVID-19 who are at risk of progression to severe disease.

Therefore, considering the advantages associated with oral pediatric drugs and their growing popularity, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global pediatric drugs market during the forecast period.

North America is expected to dominate the overall Pediatric Drugs Market:

Among all the regions, North America is expected to lead in revenue generation in the global Pediatric Drugs market. This can be ascribed to the increasing prevalence of pediatric diseases across the region, a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

The continuous research and development happening in the region are likely to accelerate the growth of pediatric drugs. For instance, according to the Pharmaceutical Research and Manufacturers of America (PhRMA) report 2020, more than 2,100 industry-sponsored pediatric clinical trials were going on in 2020 in the United States testing around 580 investigational medicines with the involvement of more than 1.2 million pediatric patients across a variety of therapeutic areas, including diseases where there is a significant unmet medical need.

The rising number of cases of developmental disorders among children is another possible factor affecting the growth of the pediatric drug market. For instance, according to the Centers for Disease Control and Prevention 2022 based on the National Survey of Parents data from 2016-2019, around 6 million children aged between 3-17 years were diagnosed with Attention-deficit/hyperactivity disorder (ADHD).

The increasing product launches and approvals in the region are other factors bolstering the growth of the pediatric drugs market in the region. For example, In May 2020, Sanofi received the US Food and Drug Administration (FDA) approval Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis.

Hence, the above-mentioned factors are expected to bolster the growth of the pediatric drug market in the United States during the forecast period.

Pediatric Drugs Market Key Players:

Some of the key market players operating in the Pediatric Drugs market include ORPHELIA Pharma, BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AstraZeneca, Sanofi, Viatris Inc., Novartis AG, GSK plc. Bayer AG, Cipla Inc., Sumitomo Pharma Co., Ltd, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Mestra Pharma, Otsuka Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, UCB S.A., Supernus Pharmaceuticals, Inc., and others.

Recent Developmental Activities in the Pediatric Drugs Market:

In November 2022, BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO(TM) (vosoritide) for Injection, indicated to increase linear growth in pediatric patients with achondroplasia five years of age and older with open epiphyses (growth plates).

In October 2022, Enzyvant announced the U.S. Food and Drug Administration (FDA) approval of RETHYMIC® which is a one-time regenerative tissue-based therapy for immune reconstitution in pediatric patients with congenital athymia.

In June 2022, Novartis AG, a leader in immuno-dermatology and rheumatology, received the U.S. Food and Drug Administration (FDA) approval for Cosentyx® (secukinumab) which is intended for the treatment of moderate to severe plaque psoriasis in pediatric patients aged six years and older.

Key Takeaways from the Pediatric Drugs Market Report Study

• Market size analysis for current pediatric drugs market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the pediatric drug market.
• Top key product developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the global pediatric drugs market.
• Various opportunities available for the other competitor in the pediatric drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2027.
• Which are the top-performing regions and countries in the current pediatric drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for pediatric drug market growth in the coming future?

Target Audience who can be benefited from this Pediatric Drugs Market Report Study

• Pediatric drugs providers
• Research organizations and consulting companies
• Pediatric Drugs -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in pediatric drugs
• Various distribution channels who want to know more about the pediatric drugs market and the latest product innovations and developments in the pediatric drugs market.

Frequently Asked Questions for the Pediatric Drugs Market:

1. What are pediatric drugs?

Pediatric drugs are those medications that are intended for treating infants, children, adolescents, and young adults suffering from any kind of disease condition.

2. What is the market for global pediatric drugs?

The global pediatric drugs market is estimated to grow at a CAGR of 4.79% during the forecast period from 2024 to 2030.

3. What are the drivers for the global pediatric drugs market?

The pediatric drugs market is slated to witness prosperity owing to factors such as the increasing prevalence of chronic diseases among children, the increasing number of clinical trials for pediatric drugs, and the growing focus on improving the safety and usability of pediatric drugs are further expected to result in the appreciable revenue growth in the pediatric drugs market during the forecast period (2024-2030).

4. Who are the key players operating in the global pediatric drugs market?

Some of the key market players operating in the pediatric drugs market include ORPHELIA Pharma, BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AstraZeneca, Sanofi, Viatris Inc., Novartis AG, GSK plc. Bayer AG, Cipla Inc., Sumitomo Pharma Co., Ltd, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Mestra Pharma, Otsuka Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, UCB S.A., Supernus Pharmaceuticals, Inc., and others.

5. Which region has the highest share in the pediatric drugs market?

North America is expected to dominate the overall pediatric drugs market during the forecast period, 2024 to 2030. This can be ascribed to the increasing research and development activities w.r.t. to pediatric drugs in the region, the increasing number of pediatric patients suffering from various diseases, high-tech medical facilities, government initiatives, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

Table of Contents

1.Pediatric Drugs Market Report Introduction

2. Pediatric Drugs Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Pediatric Drugs Market Key Factors Analysis

• 4.1. Pediatric Drugs Market Drivers
  • 4.1.1. The rise in the birth rate
  • 4.1.2. Increasing prevalence of acute and chronic diseases among children
  • 4.1.3. An increasing number of pharmaceutical trials for pediatric drugs
• 4.2. Pediatric Drugs Market Restraints and Challenges
  • 4.2.1. Side effects associated with pediatric drugs
  • 4.2.2. Stringent regulatory challenges
• 4.3. Pediatric Drugs Market Opportunities
  • 4.3.1. Growing focus on developing pediatric drugs for rare diseases
  • 4.3.2. Rising healthcare expenditure

5. Pediatric Drugs Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Pediatric Drugs Market

7. Pediatric Drugs Market Layout

• 7.1. By Indication
  • 7.1.1. Respiratory Diseases
  • 7.1.2. Cancer
  • 7.1.3. Diabetes
  • 7.1.4. Genetic Diseases
  • 7.1.5. Others
• 7.2. By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
• 7.3. By Distribution Channels
  • 7.3.1. Hospital and Retail Pharmacy
  • 7.3.2. E-commerce
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.1.2. Canada Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.1.3. Mexico Pediatric Drugs Market in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.2.2. Germany Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.2.4. Italy Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.2.5. Spain Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Pediatric Drugs Market in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.3.2. Japan Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.3.3. India Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.3.4. Australia Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.3.5. South Korea Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia Pacific Pediatric Drugs Market in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.4.2. Africa Pediatric Drugs Market in USD million (2021-2030)
    • 7.4.4.3. South America Pediatric Drugs Market in USD million (2021-2030)

8. Pediatric Drugs Market Company and Product Profiles

• 8.1. Viatris Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Sanofi
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. GSK plc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Novartis AG
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. AstraZeneca
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Johnson & Johnson Services
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Bayer AG
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Bristol-Myers Squibb Company
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Cipla Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.10. BioMarin Pharmaceutical Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Sumitomo Pharma Co., Ltd
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Gilead Sciences, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Takeda Pharmaceutical Company Limited
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. ORPHELIA Pharma
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Pfizer Inc.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Otsuka Pharmaceutical Co., Ltd.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Mestra Pharma
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. F. Hoffmann-La Roche Ltd
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. UCB S.A.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.20. Supernus Pharmaceuticals, Inc.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us